BRAF and neoplasm: They showed that SCID mice injected with human thyroid cancer cells showed no tumor volume reduction with anti-PD-L1 treatment alone, but combination treatment using the BRAF(V600E) inhibitor, PLX4720 [80] and anti-PD-L1 antibody worked synergistically to cause greater tumor volume reduction compared with treatment with PLX4720 alone.